文献速递肝肾功能剂量调整治疗药物监测与药物基因组学抗菌药物管理

危重成人ECMO患者抗菌药物群体药代动力学系统评价

Antibacterial Pharmacokinetics in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO): A Systematic Review of Population Pharmacokinetic Studies.
PubMed 文献 · Clin Pharmacokinet · 2025-12-12

该系统评价检索PubMed、Embase和Cochrane数据库至2025年3月,纳入31项危重成人ECMO患者抗菌药物群体药代动力学研究。多数研究显示ECMO特有变量(模式、流速、氧合器类型)对多数抗菌药物药代动力学无显著影响,变异主要由肾功能和肾脏替代治疗等危重症因素驱动。 dosing推荐强调个体化治疗和治疗药物监测。

要点

  • ECMO本身不持续改变多数抗菌药物在危重成人中的药代动力学。
  • 药代动力学变异主要由肾功能和肾脏替代治疗等危重症因素驱动。
  • 推荐治疗药物监测以优化暴露并减少毒性。

核心结论

  • ECMO本身不持续改变多数抗菌药物在危重成人患者中的药代动力学。
  • 观察到的药代动力学变异及给药建议主要归因于危重症因素。
  • 推荐治疗药物监测以优化暴露并最小化毒性。

研究设计与样本

  • 系统评价,检索PubMed、Embase和Cochrane数据库从建库至2025年3月。
  • 纳入标准为成人(年龄≥18岁)ECMO患者抗菌药物的群体药代动力学分析。
  • 排除非房室分析和非抗菌药物研究。
  • 共纳入31项符合条件的群体药代动力学研究。

主要发现

  • 多数研究表明ECMO特有变量(模式、流速、氧合器类型)对多数抗菌药物药代动力学无显著影响。
  • 药代动力学变异主要由肾功能和肾脏替代治疗等危重症相关因素驱动。
  • 给药建议频繁强调需要个体化治疗和治疗药物监测。

临床怎么用

  • 临床应基于肾功能和肾脏替代治疗状态调整抗菌药物剂量。
  • 推荐使用治疗药物监测优化抗菌药物暴露并减少毒性。

局限性

  • 需要进一步前瞻性研究,标准化报告协变量和临床终点以增强证据基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Achieving optimal antibacterial dosing in critically ill patients is challenging owing to the pathophysiological changes that alter drug pharmacokinetics. Extracorporeal membrane oxygenation (ECMO) further complicates pharmacokinetics, hypothesized to act as another pharmacokinetic compartment influencing drug concentrations. Ensuring therapeutic antibacterial concentrations is crucial to prevent treatment failure and resistance. This systematic review aimed to identify and evaluate published population pharmacokinetic studies of antibacterials in critically ill adult ECMO patients. METHODS: A systematic search of PubMed, Embase, and Cochrane databases was conducted from database inception to March 2025. Studies were included if they were population pharmacokinetic analyses of antibacterial agents in adult (aged ≥ 18 years) ECMO patients; non-compartmental analyses and non-antibacterial agents were excluded. Data on study characteristics, patient demographics, ECMO parameters, pharmacokinetic models, and covariates were extracted. RESULTS: The search yielded 31 eligible population pharmacokinetic studies. Most studies indicated that ECMO-specific variables (mode, flow rate, oxygenator type) did not significantly influence the pharmacokinetics of the majority of antibacterials. Instead, pharmacokinetic variability was primarily driven by critical illness-related factors, notably renal function and presence of renal replacement therapy. Dosing recommendations frequently highlighted the need for individualized therapy and therapeutic drug monitoring. CONCLUSIONS: Our findings indicate that ECMO itself does not consistently alter the pharmacokinetics of most antibacterials in critically ill adult patients. Observed pharmacokinetic variability and subsequent dosing recommendations are primarily attributable to critical illness factors. Therapeutic drug monitoring is recommended to optimize exposure but minimize toxicity. Further prospective studies with standardized reporting of covariates and clinical endpoints are needed to enhance the evidence base. CLINICAL TRIAL REGISTRATION: PROSPERO Registration and date: CRD420251165914 (15 October, 2025).

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Ren C, Huang F, Cheng V, et al. Antibacterial Pharmacokinetics in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO): A Systematic Review of Population Pharmacokinetic Studies. Clin Pharmacokinet. 2025. PMID: 41385144. doi:10.1007/s40262-025-01596-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。